Nanoparticles based on PLGA and its co-polymer: An overview

Asian Journal of Pharmaceutics

Volumn 3, Issue 4, 2009, Pages 266-273

  Muthu, M S ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

L lactide co glycolide); L lactide co glycolide) nanoparticles; Poly (D; Polymer literature; Targeted drug delivery

Indexed keywords

ALENDRONIC ACID; CISPLATIN; COPOLYMER; CYCLOSPORIN; DOXORUBICIN; ELLAGIC ACID; ESTRADIOL; FERRIC OXIDE; GENTAMICIN; MAGNETITE; NANOPARTICLE; PACLITAXEL; POLYGLACTIN; POLYMERIC NANOMICELLE; RISPERIDONE; STREPTOMYCIN; TRICLOSAN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; BIOCOMPATIBILITY; BIODEGRADATION; DIFFUSION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG MEGADOSE; EMULSION; EVAPORATION; HUMAN; NANOPRECIPITATION; NONHUMAN; PHYSICAL CHEMISTRY; PRECIPITATION; REVIEW; SALTING OUT METHOD;

EID: 77953468519     PISSN: 09738398     EISSN: 1998409X     Source Type: Journal    
DOI: 10.4103/0973-8398.59948     Document Type: Review

References (47)

1. Allemann E, Gurny R, Doelker E. Drug-loaded nanoparticles-prepa ration methods and drug targeting issues. Eur J Pharm Biopharm 1993;39:173-191
2. Muthu MS, Singh S. Targeted nanomedicines: Effective treatment modalities for cancer, AIDS and brain disorders. Nanomed 2009;4:105-118
3. Labhasetwar V, Song C, Levy RJ. Nanoparticles drug delivery systems. Adv Drug Deliv Rev 1997;24:63-85.
4. Stevanović M, Savić J, Jordović B, Uskoković D. Fabrication, in vitro degradation and the release behaviours of poly(DL-lactide-co-glycolide) nanospheres containing ascorbic acid. Colloids Surf B Biointerfaces 2007;59:215-223
5. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2006;2:8-21.
6. Verger ML, Fluckiger L, Kim Y, Hoffman M, Maincent P. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm 1998;46:137-143
7. Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: Effect of formulation variables on size distribution. Int J Pharm 2005;290:137-144
8. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Sol State Mater Sci 2002;6:319-327
9. Zhao Y, Chen W, Cai Q, Wang S, Bo J, Wu C. Erosion induced controllable release of gliclazide encapsulated inside degradable polymeric particles. Macromol Biosci 2004;4:308-313
10. Lewis DD. Controlled release of bioactive agents from lactide/glycolide polyiners. In: Chasin M, Langer R, eds. Biodegradable Polymers as Drug Delivery Systems. New York, Marcel Dekker; 1990. p. 1-41.
11. Gilding DK, Reed AM. Biodegradable polymers for use in surgery. Polyglycolic/poly(lactic acid) homo- and copolymers: 1. Polymer 1979;20:1459-1464
12. Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 1996;17:93-102.
13. Ravivarapu HB, Burton K, DeLuca PP. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. Eur J Pharm Biopharm 2000;50:263-70.
14. Li S, McCarthy SP. Influence of crystallinity and stereochemistry on the enzymatic degradation of poly(lactide)s. Macromolecules 1999;32:4454-4456
15. Schliecker G, Schmidt C, Fuchs S, Kissel T. Characterization of a homologous series of D,L-lactic acid oligomers; a mechanistic study on the degradation kinetics in vitro. Biomaterials 2003;24:3835-3844
16. Park TG. Degradation of poly(D,L-lactic acid) microspheres: Effect of molecular weight. J Control Release 1994;30:161-173
17. Vert M. Aliphatic polyesters: Great degradable polymers that cannot do everything. Biomacromolecules 2005;6:538-546
18. Makino K, Arakawa M, Kondo T. Preparation and in vitro degradation properties of polylactide microcapsules. Chem Pharm Bull 1985;33:1195-1201.
19. Göpferich A. Mechanisms of polymer degradation and erosion. Biomaterials 1996;42:1-11.
20. Visscher GE, Pearson JE, Fong JW, Argentieri GJ, Robison RL, Maulding HV. Effect of particle size on the in vitro and in vivo degradation rates of poly(DL-lactide-co-glycolide) microcapsules. J Biomed Mater Res 1988;22:733-746
21. Anderson JM. In vivo biocompatibility of implantation delivery systems and biomaterials. Eur J Pharm Biopharm 1994;40:1-8.
22. Visscher GE, Robison RL, Maulding HV, Fong JW, Pearson JE, Argentieri GJ. Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. J Biomed Mater Res 1985;19:349-365
23. Visscher GE, Robison RL, Maulding HV, Fong JW, Pearson JE, Argentieri GJ. Biodegradation of and tissue reaction to poly(DL-lactide) microcapsules. J Biomed Mater Res 1986;20:667-676
24. Ziats NP, Miller KM, Anderson JM. In vivo and in vitro interaction of cells with biomaterials. Biomaterials 1988;9:5-13
25. Ward PA. Recruitment of inflammatory cells into lung: Roles of cytokines, adhesion molecules, and complement. J Lab Clin Med 1997;129:400-404
26. Comets E, Mentré F, Kawai R, Nimmerfall F, Marbach P, Vonderscher J. Modeling the kinetics of release of octreotide from long-acting formulations injected intramuscularly in rabbits. J Pharm Sci 2000;89:1123-1133
27. Julienne MC, Alonso MJ, Gomez Amoza JL, Benoit JP. Preparation of poly(DL-lactide/glycolide) nanoparticles of controlled particle size distribution: Application of experimental designs. Drug Dev Ind Pharm 1992;18:1063-1077
28. Yoo HS, Oh JE, Lee KH, Park TG. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm Res 1999;16:1114-1118
29. Allémann E, Leroux JC, Gurny R, Doelker E. In vitro extended-release properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure. Pharm Res 1993;10:1732-1737
30. Fessi H, Puisieux F, Devissaguet JP. Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles. United States Patent 1992;5:118-528.
31. Jung T, Breitenbach A, Kissel T. Sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide)s facilitate the preparation of small negatively charged biodegradable nanospheres. J Control Release 2000;67:157-169
32. Dreis S, Rothweiler F, Michaelis M, Cinatl J Jr, Kreuter J, Langer K. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm 2007;341:207-214
33. Piñón-Segundo E, Ganem-Quintanar A, Alonso-Pérez V, Quintanar- Guerrero D. Preparation and characterization of triclosan nanoparticles for periodontal treatment. Int J Pharm 2005;294:217-232
34. Dong Y, Feng SS. Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005;26:6068-6076
35. Bala I, Bhardwaj V, Hariharan S, Kharade SV, Roy N, Ravi Kumar MN. Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration. J Drug Target 2006;14:27-34.
36. Pandey R, Khuller GK. Nanoparticle-based oral drug delivery system for an injectable antibiotic - streptomycin. Evaluation in a murine tuberculosis model. Chemotherapy 2007;53:437-441
37. Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MN. Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release 2007;119:77-85.
38. Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Kumar MN. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Control Release 2007;119:197-206.
39. Lecaroz MC, Blanco-Prieto MJ, Campanero MA, Salman H, Gamazo C. Poly(D,L-lactide-coglycolide) particles containing gentamicin: Pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice. Antimicrob Agents Chemotherr 2007;51:1185-1190
40. Muthu MS, Rawat MK, Mishra A, Singh S. PLGA nanoparticle formulations of risperidone: Preparation and neuropharmacological evaluation. Nanomedicine 2009;5:323-333
41. Davaran S, Rashidi MR, Pourabbas B, Dadashzadeh M, Haghshenas NM. Adriamycin release from poly(lactide-coglycolide)-polyethylene glycol nanoparticles: Synthesis, and in vitro characterization. Int J Nanomedicine 2006;1:535-539
42. Choi SW, Kim JH. Design of surface-modified poly(D,L-lactide-co- glycolide) nanoparticles for targeted drug delivery to bone. J Control Release 2007;122:24-30.
43. Mattheolabakis G, Taoufik E, Haralambous S, Roberts ML, Avgoustakis K. In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur J Pharm Biopharm 2007;71:190-195
44. Duguet E, Vasseur S, Mornet S, Devoisselle JM. Magnetic nanoparticles and their applications in medicine. Nanomed 2006;1:157-168
45. Ngaboni Okassa L, Marchais H, Douziech-Eyrolles L, Cohen-Jonathan S, Soucé M, Dubois P, et al. Development and characterization of sub-micron poly(D,L-lactide-co-glycolide) particles loaded with magnetite/maghemite nanoparticles. Int J Pharm 2005;302:187-196
46. Jones M, Leroux J. Polymeric micelles - a new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999;48:101-111
47. Yoo HS, Park TG. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Release 2001;70:63-70.